Novel Janus Kinase Inhibitors in the Treatment of Dermatologic Conditions

This article discusses baricitinib, a JAK1 and JAK2 inhibitor, as an approved and promising treatment for alopecia areata but reports no new clinical results.

This article describes the development milestones and recent approvals of ritlecitinib for treating severe alopecia areata, with approvals in the USA and Japan and ongoing regulatory reviews in other regions.

In this study of seven randomized clinical trials, JAK inhibitors were associated with improved hair regrowth outcomes in alopecia areata patients compared to placebo, with oral administration being more effective than external application, though longer trials are needed to confirm safety and effectiveness.

This study reviewed 39 studies with 3204 patients to identify characteristic trichoscopic findings in alopecia areata, highlighting yellow and black dots, broken, short vellus, and tapering hairs as key indicators. It found no single diagnostic trichoscopic finding but observed trichoscopy's utility in monitoring treatment response.

Ritlecitinib effectively treats alopecia areata and is well-tolerated.

This study found that patients with rheumatoid arthritis, atopic dermatitis, and alopecia areata receiving baricitinib had low incidence rates of adverse events, especially among low-risk individuals, with varying rates among those at higher risk.

This review discusses the potential of JAK inhibitors as a promising treatment strategy for alopecia areata, highlighting their mechanism and recent FDA approval based on clinical trial efficacy.

In two phase 3 trials, this study found that oral baricitinib significantly improved hair regrowth compared to placebo in adults with severe alopecia areata after 36 weeks, though longer trials are needed to ascertain its long-term efficacy and safety.

This review discusses the composition, activation, and regulation of the JAK/STAT pathway and highlights its role and inhibitors in various diseases, but reports no new experimental results.

JAK inhibitors show promise for treating alopecia areata, but more research is needed.

This article reviews the JAK signaling pathway and the development of ruxolitinib cream as a targeted treatment for inflammatory skin diseases, reporting no new clinical results.

This review discusses the immunological basis and development of Janus kinase inhibitors for treating skin diseases and reports no new clinical findings.

This review discusses the role of the JAK-STAT pathway in autoimmune skin diseases and suggests potential therapeutic benefits of JAK inhibitors, but reports no new experimental results.

This article reviews the epidemiology, clinical evaluation, and pathogenesis of alopecia areata and highlights recent advancements, but it does not report new clinical findings.

Alopecia Areata is an autoimmune condition causing hair loss with no cure and treatments that often don't work well.

This study suggests that human hair follicles may actively suppress natural killer cells, which contrasts with the observed defects in NK cell regulation in alopecia areata.